RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
  Adrenergics
  Analgesics
  Anti Cancer Drugs
  Anti-Clotting Drugs
  Anti-Inflammatory
  Antibiotics
  Anticholesterol
  Antihypertensives
  Antivirals
  Fatty Acids
  Hypnotics
  Metals
  PPI
  Surfactants
  Varenicline
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Pharmacology Channel

subscribe to Pharmacology newsletter
Latest Research : Pharmacology

   EMAIL   |   PRINT
October and November 2004 Lot of Neurontin Recalled

Apr 24, 2005 - 7:53:00 AM
Patients should not stop taking Neurontin before consulting with their physician. If they filled a prescription for the product in 100 mg strength between October 1, 2004 and March 15, 2005 and are concerned that any unused capsules may be part of the recalled lot, they should contact their pharmacist.

 
[RxPG] Pfizer Inc voluntarily recalled one lot (40,000 bottles) of 100 mg capsules of its epilepsy medication, Neurontin, after a manufacturing mechanical failure resulted in some bottles containing empty or partially filled capsules.

Pfizer said only 100 mg strength capsules from lot #15224V --distributed in October and November 2004 -- are included in the recall. The production lot was distributed only in the United States. No other Neurontin lots were affected.

The company said it is possible that patients taking Neurontin to control epilepsy could experience seizures from a missed dose of the product.

Although pharmacists and Pfizer distributors were notified on February 23 of the recall and pharmacists were instructed to immediately contact any of their customers using Neurontin, Pfizer wants to ensure full patient awareness.

The company has worked closely with the FDA throughout the recall process. Patients should not stop taking Neurontin before consulting with their physician. If they filled a prescription for the product in 100 mg strength between October 1, 2004 and March 15, 2005 and are concerned that any unused capsules may be part of the recalled lot, they should contact their pharmacist.

If consumers have questions about the recall, they should contact Pfizer Medical Information at 1-800-438-1985.

Pfizer said the recall of the affected lot will not result in a shortage of Neurontin 100 mg capsules.



Publication: U.S. Food and Drug Administration (FDA)
On the web: www.pfizer.com 

Advertise in this space for $10 per month. Contact us today.


Related Pharmacology News
Palliative radiotherapy for bone metastases in elderly patients improves quality of life
Research shows promise for microwave ablation to relieve painful bone and soft-tissue tumors
Experimental study suggests bone-marrow grafts show promise for some sufferers of low-back pain
Study suggests dexmedetomidine before surgery reduced remifentanil-induced hyperalgesia
Research examines effects of opioids on patients with sickle cell disease
Full range of treatment settings and their effects on radiofrequency heat lesion size
High-dose opioids disturb hormones long-term, but mental and physiologic function improves
Web-based tools found to enhance recruitment and prescreening for clinical pain trials
Experimental study suggests bone-marrow grafts show promise for some sufferers of low-back pain
Study: Pain improves during first year but mental-health problems linger

Subscribe to Pharmacology Newsletter

Enter your email address:


 Additional information about the news article
If consumers have questions about the recall, they should contact Pfizer Medical Information at 1-800-438-1985.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)